1.
Akpola
t T, Utaş C. Hemodiyaliz Hekimi El Kitabı. Kayseri, Anadolu Yayıncılık, 2001.
2. England BK, Mitch WE. Mechanisms of progression of renal insufficiency. In: Massry SG, Glassock RJ (eds), Textbook of Nephrology. 3rd ed, Volume 2. Baltimore, Williams and Wilkins, 1995: 1261-1269.
3. Heinzelmann M, Mercer-Jones MA, Passmore JC. Neutrophils and renal failure. Am J Kidney Dis 1999; 34:384-399.
4. Sies H. Oxidative stress: Oxidants and antioxidants. Exp Physiol 1997; 82:291-295.
5. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, et al. Advan¬ced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49:1304-1313.
6. Amore A, Coppo R. Immunological basis of inflammation in di¬alysis. Nephrol Dial Transplant 2002; 17 (Suppl 8):S16-S24.
7. Descamps-Latscha B, Drüeke T, Witko-Sarsat V. Dialysis-induced oxidative stress: Biological aspects, clinical consequences, and therapy. Semin Dial 2001;14:193-199.
8. Sarpkaya
S
. Kronik Böbrek Yetmezliğinde Protein Oksidasyonu. Yüksek Lisans Tezi, Erciyes Üniversitesi Sağlık Bilimleri Enstitü¬sü, Kayseri 2003, ss 68.
9. Himmelfarb J, McMenamin ME, Loseto G, Heinecke JW. Myelo-peroxidase-catalyzed 3-chlorotyrosine formation in dialysis pati¬ents. Free Radic Biol Med 2001; 3:1163-1169.
10. Mimic-Oka J, Simic T, Pljesa M, Stupar N, Turkovic S. Oxidative modifications of plasma proteins in different stages of chronic re¬nal failure. Med Biol 2001; 8:1-5.
11. Weiss SL. Tissue destruction by neutrophils. N Eng J Med 1989;
320:365-376.
12. Paul JL. Influence of uremia on polymorphonuclear leukocytes oxidative metabolism in end-stage renal disease and dialyzed pa¬tients. Nephron 1991; 57:428-432.
13. Hörl HW, Riegel W, Schollmeyer P. Different complement and granulocyte activation in patient dialyzed with PMMA dialyzers. Clin Nephrol 1986; 25:304-307.
14. Höllgren R, Venge P, Danielson BG. Neutrophil and eosinophil degranulation during hemodialysis are mediated by the dialysis membrane. Nephron 1982; 32:329-334.
15. Hörl WH, Riegel W, Steinhauer HB, et al. Granulocyte activation during hemodialysis. Clin Nephrol 1986; 26:30-34.
16. Kuwahara T, Maskert M, Wauters JP. Neutrophil oxygen radical production by dialysis membranes. Nephrol Dial Transplant 1988; 3:661-665.
17. Chen MF, Chang CL, Liou SY. Increase in resting levels of supe-roxide anion in the whole blood of uremic patients on chronic hemodialysis. Blood Purif 1998; 16:290-300.
18. Gündüz Z, Düşünsel R, Köse K, Utaş C, Doğan P. The effect of di-alyzer reuse on plasma antioxidative mechanisms in patients on re¬gular hemodialysis treatment. Free Radic Biol Med 1996; 21: 225-231.
19. Hörl WH, Feinstein EL, Wanner C, et al. Plasma levels of main glanulocyte components during hemodialysis: comparison of new and reused dialyzers. Am J Nephrol 1990; 10:53-57.
20. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. Pro¬tein carbonyl groups as biomarkers of oxidative stress. Clin Chim
Acta 2003; 329:23-38.
21. Massy ZA, Nguyen-Khoa T, Beauvais CH. Oxidative stress and chronic renal failure: markers and management. J Nephrol 2002; 15:336-341.
22. Miyata T, Sugiyama S, Saito A, Kurokawa K. Reactive carbonyl compounds related uremic toxicity ("carbonyl stress"). Kidney Int
2001; 59:25-31.
23. Davies MJ, Fu S, Wang H, Dean RT. Stable markers of oxidant da¬mage to proteins and their application in the study of human di¬sease. Free Radic Biol Med 1999; 27:1151-1163.
24. Dean RT, Fu S, Stocker R, Davies MJ. Biochemistry and pathology of radical-mediated protein oxidation. Biochem J 1997; 324:1-18.
25. Stadtman ER, Berlett BS. Reactive oxygen-mediated protein oxi¬dation in aging and disease. Chem Res Toxicol 1997; 10:485-494.
26. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic comp¬lications. Diabetes 1999; 48:1-8.
27. Himmelfarb J, McMonagle E, McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney
Int 2000; 58:2571-2578.
28. Donate T, Herreros A, Martinez E, et al. Protein oxidative stress
in dialysis patients. Adv Perit Dial 2002; 18:15-17.
29. Sarpkaya
S
, Köse K, Yazıcı C, Utaş C. Kronik böbrek yetmezliğin¬de protein oksidasyonu. Erciyes Üniversitesi Sağlık Bilimleri Ens¬titüsü Dergisi 2003; 12:42-48.
30. Himmelfarb J, McMonagle E. Albumin is the major plasma prote¬in target of oxidant stress in uremia. Kidney Int 2001; 60:358-363.
31. Körmöczi GF, Wölfel UM, Rosenkranz AR, et al. Serum proteins modified by neutrophil-derived oxidants as mediators of neutrop-hil stimulation. J Immunol 2001; 167:451-460.
32. Miyata T, Strihou CY, Kurokawa K, Baynes JW. Alterations in no-nenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int
1999; 55:389-399.
33. Kumano K, Yokota S, Go M, et al. Quantitative and qualitative changes of serum albumin in CAPD patients. Adv Perit Dial 1992;
8:127-130.
34. Lameire N, Vanholder R, De Smet R. Uremic toxins and peritone¬al dialysis. Kidney Int 2001; 59:292-297.
35. Friedlander MA, Yu Ching W, Elgawish A, Monnier VM. Early and advanced glycosylation end products kinetics of formation and clearance in peritoneal dialysis. J Clin Invest 1996; 97:728-735.
36. Erdoğan C, Ünlüçerçi Y, Türkmen A, et al. The evaluation of oxi-dative stress in patients with chronic renal failure. Clin Chim Ac-
ta 2002; 322:157-161.
37. Descamps-Latscha B, Witko-Sarsat V. Importance of oxidatively modified proteins in chronic renal failure. Kidney Int 2001; 59
(Suppl.78):S108-S113.
Official Journal of the Turkish Society of Nephrology / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
123
9 Oxidative Stress and "Biomarker"s in Chronic Renal Failure
38. Nguyen-Khoa T, Massy ZA, De Bandt PJ, Kebede M, Salama L.
Oxidative stress and hemodialysis: role of inflammation and du¬ration of dialysis treatment. Nephrol Dial Transplant 2001; 16:
335-340.
39. Witko-Sarsat V, Friedlander M, Nguyen-Khoa T, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998;
161:2524-2532.
40. Wayner DDM, Burton GW, Ingold KU, Barclay LRC, The relative
contributions of vitamin E, urate, ascorbate and proteins to the total peroxyl radical-trapping antioxidant activity of human blo¬od plasma. Biochim Biophys Acta 1987; 924:408-419.
41. Hu ML, Locie S, Cross CE, Motchnik P, Halliwell B. Antioxidant protection against hypochlorous acid in human plasma. J Lab
Clin Med 1993; 121:257-262.
42. Wlodek PJ, Iciek MB, Milkowski A, Smolenski OB. Various forms of plasma sistein and its metabolities in patients undergoing he-
modialysis. Clin Chim 2001; 304:9-18.
43. Prior RL, Cao G. In vivo total antioxidant capacity: Comparison of different analytical methods. Free Radic Biol Med 1999; 27:
1173-1181.
44. Kuroda M, Asaka S, Tofuku Y, Takeda R. Serum antioxidant acti¬vity in uremic patients. Nephron 1985; 41:293-298.
45. Jackson P, Loughrey CM, Lightbody JH, McNamee PT, Young IS. Effect of hemodialysis on total antioxidant capacity and serum antioxidant in patients with chronic renal failure. Clin Chem 1995;
41:1135-1138.
46. Clermont G, Lecour S, Lahet JJ, et al. Alteration in plasma antioxi-dant capacities in chronic renal failure and hemodialysis patients: a possible explanation for the increased cardiovascular risk in these patients. Cardiovasc Res 2000; 47:618-623.
47. Bergesio F, Monzani G, Ciuti R, et al. Total antioxidant capacity (TAC): is it an effective method to evaluate the oxidative stress in uraemia. J Biolumin Chemilumin 1998; 13:315-319.
48. Nguyen-Khoa T, Massy ZA, Witko-Sarsat V, et al. Critical evalu¬ation of plasma and LDL oxidant-trapping potential in hemodi-alysis patients. Kidney Int 1999; 56:747-753.
49. Benzie IFF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "Antioxidant Power": The FRAP assay. Anal Bi-
ochem 1996; 239:70-76.
50. Parthasarathy S, Santanam N, Ramachandran S, Meilhac O. Oxi-dants and antioxidants in atherogenesis: an appraisal. J Lipid Res
1999; 40:2143-2157.
51. Shoji T, Nishizawa Y, Kawagishi T, et al. Atherogenic lipoprote-
in changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. Atherosclerosis
1997; 131: 229-236.
52. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous mo¬nitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 1989; 6:67-75.
53. Nguyen-Khoa T, Massy ZA, Witko-Sarsat V, Canteloup S, Kebede M. Oxidized low-density lipoprotein induces macropha-ge respiratory burst via its protein moiety: a novel pathway in atherogenesis. Bichem Biophys Res Commun 1999; 263: 804-809.
54. Kaneda H, Taguchi J, Ogasawara K, Lizawa T, Ohna M. Increased level of advanced oxidation protein products in patients with co¬ronary artery disease. Atherosclerosis 2002; 162:221-225.
55. Carr AC, McCall MR, Frei B. Oxidation of LDL by myeloperoxida-se and reactive nitrogen species. Arterioscler Thromb Vasc Biol
2000; 20:1716-1723.
56. Maggi E, Bellazzi R, Falaschi F, et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated athe¬rosclerosis. Kidney Int 1994; 45:876-883.
57. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascu¬lar disease in chronic renal disease. J Am Soc Nephrol 1998; 9:
916-923.
58. Kitiyakara C, Gonin J, Massy Z, Wilcox CS. Non-traditional cardi¬ovascular disease risk factors in end-stage renal disease: oxidati-ve stress and hyperhomocysteinemia. Curr Opin Nephrol Hyper-
tens 2000; 9:477-487.
59. Inose K, Ono K, Tsutida A. Active inhibitory effect of nafamostat mesylate against the evaluation of plasma myeloperoxidase du¬ring hemodialysis. Nephron 1997; 75:420-425.
60. Ward RA, Ouseph R, McLeish KR. Effects of high-flux hemodialy-sis on oxidant stress. Kidney Int 2003; 63:353-359.
61. Wlodek PJ, Kurcharczyk J, Sokolovska MM, et al. Alteration in plasma levels of nonprotein sulfhydryl compounds and S-nitro-sothiols in chronic renal failure patients. Clin Chim Acta 2003;
327:87-94.
62. Nagase S, Aoyagi K, Hirayama A, et al. Favorable effect of hemo-dialysis on decreased serum antioxidant activity in hemodialysed patients demonstrated by electron spin resonance. J Am Soc
Nephrol 1997; 8:1157-1163.
63. Witko-Sarsat V, Gausson V, Nguyen AT, et al. AOPP-induced ac¬tivation of human neutrophil and monocyte oxidative metabo¬lism: a potential target for N-acetylcysteine treatment in dialysis
patients. Kidney Int 2003; 64:82-91.
Thank you for copying data from http://www.arastirmax.com
